.svg)
Axisymmetric bis-tridentate Ir(iii) photoredox catalysts for anticancer phototherapy under hypoxia
| dc.contributor.author | Wei L.; Kushwaha R.; Dao A.; Fan Z.; Banerjee S.; Huang H. | |
| dc.date.accessioned | 2025-05-23T11:18:08Z | |
| dc.description.abstract | A novel axisymmetric bis-tridentate Ir(iii) photocatalyst (Ir3) with synergetic type I/II photosensitization and photocatalytic activity was reported. Ir3 exhibited high photocytotoxicity toward drug-resistant cancer cells under normoxia and hypoxia. The photoactivated anticancer mechanism of Ir3 were investigated in detail. Overall, this new photo-redox catalyst can overcome hypoxia and drug resistance-related problems in clinical anticancer therapy. © 2023 The Royal Society of Chemistry. | |
| dc.identifier.doi | https://doi.org/10.1039/d2cc06721h | |
| dc.identifier.uri | http://172.23.0.11:4000/handle/123456789/8164 | |
| dc.relation.ispartofseries | Chemical Communications | |
| dc.title | Axisymmetric bis-tridentate Ir(iii) photoredox catalysts for anticancer phototherapy under hypoxia |